Advanced Biodesign
- Biotech or pharma, therapeutic R&D
ADVANCED BIODESIGN (ABD) has been investigating cancer resistance and relapse mechanisms. Leveraging its expertise and collaborations with renowned academic institutes, ABD confirmed the pivotal role of ALDH1 enzymes in cancer cell metabolism and immunomodulation, demonstrating their key role in cancer resistance and relapse. Elevated ALDH1 activity is heightened in tumors resistant to chemotherapies, correlating with an unfavorable prognosis in both solid and liquid cancers.
ABD owns a proprietary pipeline of ALDH1 inhibitors, potentially revolutionizing patient care. ABD's most advanced drug candidate, ABD-3001, entered clinical investigation in 2022 as part of the ODYSSEY Phase 1 clinical trial (NCT05601726) for Acute Myeloid Leukemia.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}